Inflammatory Bowel Disease Juvenile Rheumatoid Arthritis Crohn Disease Bone Marrow Suppression Methotrexate Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Nieuwenhuis EE, Blumberg RS. The role of the epithelial barrier in inflammatory bowel disease, In:Blumberg RE, Neurath MF, editors. Immune mechanisms in inflammatory bowel disease. Springer Science, Landes Bioscience, 2005;109–116.Google Scholar
  3. 3.
    Sandborn WJ. Evidence-based treatment algorithm for mild to moderate Crohn’s disease. Am J Gastroenterol 2003;98:S1–S5.PubMedCrossRefGoogle Scholar
  4. 4.
    Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: Acute and 1-year outcomes in newly diagnosed children with Crohn disease. Clin Gastroenterol Hepatol 2006;4:1124–29.PubMedCrossRefGoogle Scholar
  5. 5.
    Jacobstein DA, Mamula P, Markowitz JE, Leonard M, Baldassano RN. Predictors of immunomodulatory use as early therapy in pediatric Crohn disease. J Clin Gastroenterol 2006;40:145–148.PubMedCrossRefGoogle Scholar
  6. 6.
    Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology 2000;119:895–902.PubMedCrossRefGoogle Scholar
  7. 7.
    Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Panaccione R. Methotrexate: lessons from rheumatology. Can J Gastroenterol 2005;9:541–42.Google Scholar
  9. 9.
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn disease. The North American Crohn study group investigators. N Engl J Med 1995;332:292–97.PubMedCrossRefGoogle Scholar
  10. 10.
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn disease. North American Crohn study group investigators. N Engl J Med 2000;342:1627–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Uhlen S, Belbouab R, Narebski K, et al. Efficacy of Methotrexate in Pediatric Crohn’s Disease: A French Multicenter Study. Inflamm Bowel Dis 2006;12:1053–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric crohn’s disease. Am J Gastroenterol 2007;102:1–9.CrossRefGoogle Scholar
  13. 13.
    Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Baron TH, Truss CD, Elson CO. Low-dose methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38:1851–56.Google Scholar
  15. 15.
    Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th edition. New York: McGraw-Hill, 1996;1243–47.Google Scholar
  16. 16.
    Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36–43.PubMedGoogle Scholar
  17. 17.
    Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Paillot R, Genestier L, Fournel S, et al. Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc 1998;30:2348–2350.PubMedCrossRefGoogle Scholar
  19. 19.
    Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000;47:247–57.Google Scholar
  20. 20.
    Johnston A, Gudjonsson JE, Sigmundskottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation of adhesion molecules. Clin Immunol 2005;114:154–63.PubMedCrossRefGoogle Scholar
  21. 21.
    Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739–55.PubMedCrossRefGoogle Scholar
  22. 22.
    vanDieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE, van derWoude J. Revisiting the immunomodulators tacrolimus. Methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006;12:311–27.CrossRefGoogle Scholar
  23. 23.
    Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2004;98:530–37.CrossRefGoogle Scholar
  24. 24.
    Angelis-Stoforidis P, Vajda FJE, Christophidis N. Methotrexate polyglutamate levels in ciruculating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheum 1999;17:313–20.Google Scholar
  25. 25.
    Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn disease: long-term safety and toxicity. Am J Gastroenterol 2000;95:1730–34.PubMedGoogle Scholar
  26. 26.
    Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn disease. Aliment Pharmacol Ther 2001;15:35–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Kurnik D, Loebstein R, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn disease. Aliment Pharmacol Ther 2003;18:57–63.PubMedCrossRefGoogle Scholar
  28. 28.
    Stephens MC, Baldassano RN, York A, Widemann B, Pitney AC, Jayaprakash N, Adamson PC. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Peditr Gastroenterol Nutr 2005;40:445–49.CrossRefGoogle Scholar
  29. 29.
    Alfadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn disease. Cochrane Database Syst Rev 2005;1:CD003459.PubMedGoogle Scholar
  30. 30.
    Alsufyani K, Ortiz-Alvarez O, Cabral DA, tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004;31:179–82.PubMedGoogle Scholar
  31. 31.
    Kozarek RA, Patterson DJ, Gelfand MD, Alin Botoman A, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:335–56.Google Scholar
  32. 32.
    Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997;11:569–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn disease: a randomized, investigator-blind study. Dig Liver Dis 2003;35:619–27.PubMedCrossRefGoogle Scholar
  34. 34.
    Mate-Jimenez J, Hermida C, Canter-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227–33.PubMedGoogle Scholar
  35. 35.
    Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn disease after 6-mercaptopurine. J Pediatr 1998;132:830–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849–57.PubMedCrossRefGoogle Scholar
  37. 37.
    Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The pediatric rheumatology collaborative study group and the cooperative children’s study group. N Engl J Med 1992;326:1043–49.PubMedCrossRefGoogle Scholar
  38. 38.
    Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992;120:468–73.PubMedCrossRefGoogle Scholar
  39. 39.
    Batres LA, Gabriel CA, Tsou VM. Methotrexate-induced esophagitis in a child with crohn disease. J Pediatr Gastroenterol Nutr 2003;37:514–16.PubMedCrossRefGoogle Scholar
  40. 40.
    Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 1988;19:145–56.PubMedGoogle Scholar
  41. 41.
    Kremer JM, Alarcon GS, Lightfood RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guideline for monitoring liver toxicity. Arthritis Rheum 1994;37:316–28.PubMedCrossRefGoogle Scholar
  42. 42.
    Kugathasan S, Newman AJ, Dahms BB, Boyle JT. Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term weekly methotrexate therapy. J Pediatr 1996;128:149–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Te HS, Schiano TD, Hanauer SB, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150–56.PubMedCrossRefGoogle Scholar
  44. 44.
    Rains CP, Noble S, Faulds D. Sulfasalazine: A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50:137–56.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Joel R. Rosh
    • 1
  1. 1.Director, Pediatric Gastroenterology, Atlantic Health/Goryeb Children’s HospitalUMD—New Jersey Medical SchoolMorristownUSA

Personalised recommendations